Amalgamated Bank increased its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 3.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,232 shares of the biotechnology company’s stock after buying an additional 168 shares during the quarter. Amalgamated Bank’s holdings in bluebird bio were worth $550,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Teacher Retirement System of Texas raised its position in bluebird bio by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after buying an additional 53 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 150 shares during the last quarter. Winfield Associates Inc. boosted its holdings in shares of bluebird bio by 6.1% in the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 162 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 295 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of bluebird bio by 2.6% in the 1st quarter. Legal & General Group Plc now owns 13,944 shares of the biotechnology company’s stock valued at $1,272,000 after acquiring an additional 357 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/04/amalgamated-bank-raises-position-in-bluebird-bio-inc-blue.html.

Several equities research analysts have weighed in on the company. BidaskClub raised bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Morgan Stanley restated a “hold” rating on shares of bluebird bio in a research note on Wednesday, August 9th. Leerink Swann restated an “outperform” rating and issued a $120.00 target price on shares of bluebird bio in a research note on Saturday. Jefferies Group LLC reaffirmed a “buy” rating and set a $88.00 target price on shares of bluebird bio in a report on Friday, August 11th. Finally, Cantor Fitzgerald set a $39.00 price target on bluebird bio and gave the company a “sell” rating in a research report on Saturday, June 24th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $109.61.

In related news, insider Nick Leschly sold 46,833 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $122.27, for a total transaction of $5,726,270.91. Following the sale, the insider now owns 289,368 shares of the company’s stock, valued at $35,381,025.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director James Mandell sold 1,000 shares of the stock in a transaction on Monday, August 14th. The shares were sold at an average price of $95.95, for a total value of $95,950.00. Following the sale, the director now directly owns 1,000 shares in the company, valued at approximately $95,950. The disclosure for this sale can be found here. Over the last three months, insiders have sold 128,829 shares of company stock valued at $15,480,499. Corporate insiders own 3.90% of the company’s stock.

bluebird bio, Inc. (BLUE) opened at 127.55 on Wednesday. The company’s 50-day moving average price is $118.73 and its 200-day moving average price is $100.09. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $143.50. The stock’s market cap is $5.81 billion.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The firm’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same period last year, the company earned ($1.59) EPS. Equities analysts forecast that bluebird bio, Inc. will post ($6.77) earnings per share for the current year.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.